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Abstract
Background: Adenomatous polyposis coli (APC) and Ataxia-telangiectasia-mutated (ATM) gene products have an
important role in cell cycle control and maintenance of genomic stability. Our aim was to analyze ATM and APC
methylation and its relationship with oral squamous cell carcinoma (OSCC).
Materials and methods: Eighty-four OSCC tissues that have been fixed in paraffin along with 57 control oral
samples have been used for analyzing promoter methylation of ATM and APC genes by Methylation Specific
Polymerase Chain Reaction (MS-PCR). In addition, 10 cases of OSCC and the same of matched controls were
examined for estimating expression of the above mentioned genes using Real-Time Reverse-Transcription PCR.
Results: Observed promoter methylations were 71.42% and 87.71% for the APC gene and 88.09% and 77.19% for
the ATM gene in cases and controls, respectively. Analysis of these data showed that promoter methylation at APC
was significantly different in cases compared to healthy controls (p = 0.01), but no difference was detected for the
ATM gene. Furthermore, the mRNA expression levels did not differ statistically between cases and controls for both
ATM (cases = 9, controls = 10) and APC (cases = 11, controls = 10) genes.
Conclusions: Our results, for the first time, provide methylation profiles of ATM and APC genes in a sample of
patients with OSCC in a southeast Iranian population. The present data support related evidence of APC
methylation effect on OSCC development.
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Introduction
Oral squamous cell carcinoma (OSCC) is one of the
most frequently diagnosed types of head and neck can-
cers based on epidemiological reports [1]. It has been
suggested that OSCC can arise in the course of accumu-
lation of multiple genetic alterations [2], for which accu-
rate molecular mechanisms regarding its pathogenesis
remain to be understood.
In addition to genetic changes, any alteration in epige-
netic information such as DNA methylation, histone
modifications, chromatin structure, microRNA, and
other genomic functions may make an individual sus-
ceptible to developing cancer [3]. Hyper-methylation of
promoter CpG islands and repetitive DNA sequences
has been recognized as one of the most important varia-
tions in the progression of the cancer [4]. Growing data
points to the critical role of CpG island hypermethyla-
tion in genes implicated in apoptosis, cell cycle regula-
tion, and cellular differentiation in various types of
cancer [5,6]. In respect to OSCC development, current
studies show that epigenetic silencing of cancer-linked
genes through DNA methylation plays a significant role
[7,8]. In the genomes of mammals, methylation takes
place at CpG islands that are located in the promoter
region of approximately half of the genes. These are
heritable throughout mitosis and are copied to the new
strand by DNA methylatransferase-1 during DNA repli-
cation [9]. Although the accurate function of DNA
methylation in OSCC is not fully understood, it is well
known that gene expression is influenced by DNA
methylation. Overall, DNA methylation represses
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vation [10].
In this study, we examined hypermethylation of
ataxia-telangiectasia-mutated (ATM) and adenomatous
polyposis coli (APC) genes and their expression profiles
in patients with OSCC.
ATM gene is located on chromosome 11q22-23[11],
and encodes a serine-threonine kinase that belongs to
the phosphatidylinositol-3 kinase (PI-3K) family. This
enzyme plays an essential role in the pathways activated
by DNA breaks [12]. In reaction to various agents that
damage DNA, ATM phosphorylates p53, which increases
its stabilization and expression level, ultimately leading to
cell cycle arrest, DNA repair, and apoptosis[13]. How-
ever, the possible link between p53 and ATM deactiva-
tion in the expansion and development of human tumors
is not well established. A number of groups have identi-
fied the 11q22-23 locus as a common deletion site in
head and neck squamous cell carcinoma (HNSCC)[14].
However, it is presently unclear whether ATM is exhibit-
ing this deletion in the HNSCCs, because this protein has
an important role in preserving genomic homeostasis in
HNSCC and other types of cancers [15,16].
APC gene is located on chromosome 5q21-q22 and
encodes a homodimeric protein that functions in the
cytoplasm and nucleus of the cells and has an important
role in cell cycle arrest and apoptosis [17]. The wild-
type APC protein acts as a vital controller in the Wnt-
signaling pathway [18]. A relationship between methyla-
tion of CpG sites of APC gene and different types of
cancer have recently been observed [19,20]. However,
the associations of APC and ATM genes’ methylation
with gene silencing mechanisms have not yet been fully
elucidated. The aim of our study was to investigate the
effect of hypermethylation of APC and ATM genes and
their expression profile in patients with OSCC.
Results
Detection of methylation in APC and ATM genes using
MS-PCR
Results of the APC and ATM genes methylation status
in patients with OSCC and healthy individuals and their
relationship with clincopathalogical parameters are
shown in Tables 1 and 2. There was no significant asso-
ciation between methylation status of ATM and APC
and clinical parameters such as sex, age, and tumor
stages. As shown in table 3, methylation of ATM was
found in 88.09% (74 out of 84) of patients with OSCC
and in 77.19% (44 out of 57) of healthy controls. Simi-
larly, APC gene methylation was 71.42% (60 out of 84)
in cases and 87.71% (50 out of 57) in controls. Compari-
son of methylation status between cases and controls
revealed statistically significant differences for APC (p =
0.01) and insignificant for ATM. This part of result has
been analyzed by c2 and t tests.
Analysis of relative APC and ATM genes expression
Analysis of relative gene expression (2
-ΔΔCT)f o rA P C
and ATM between cases and controls was done by
Mann-Witny test. As shown in Table 4, APC relative
Table 1 Relationship between APC promptor methylation and clinicopathology parameters in healthy controls and
cases
Characteristics Controls * APC Methylation status P value Cases APC methylation status **P
value
N = 57 N=84
Present
N (%)
Absent
N (%)
Present
N (%)
Absent
N (%)
Mean age 39.07 ± 14 54.14 ± 18
< 50 46 39 (84.8) 7 (15.2) 26 20(76.93) 6 (23.07)
0.9 0.2
> 50 11 10(90.90) 1 (9.1) 58 39(67.24) 19(32.76)
Sex
Male 21 18 (85.7) 3 (14.3) 39 32(82.05) 7 (17.95)
0.06 0.72
Female 36 32(88.88) 4 (11.12) 45 28(62.22) 17(37.78)
Stage 0.05
I - - - - 18 11(61.11) 7(38.89)
II 18 15(83.33) 3(16.64)
III 43 31(72.08) 12(27.92)
IV 5 2(40) 3(60)
* Methylation present: means that PCR product is produced only with methylated primers.
Methylation absent: means that PCR product is produced only with unmethylated primers.
**Chi-square test
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7.4) and 0.95 ± 1.31 for controls (n = 10, range: 0.002-
3.43). The ATM data were 0.5 ± 0.9 for cases (n = 9,
range: 0.005-2.94) and 1.48 ± 2.2 for controls (n = 10,
range: 0.0001-6.27). The difference was not statistically
significant between patients and healthy individuals.
Discussion
In this study, our results indicated a significant differ-
ence in methylation profile between cases and controls
for APC gene (p = 0.01), but not for ATM.
In recent years, gene expression, as well as other mole-
cular profiling, has been used as biological tools for diag-
nosis of cancer [21,22]. These molecular approaches also
have the potential to explore molecular mechanisms of
the disease and to pave the road to targeted cancer fight-
ing drugs and advanced treatments [23]. APC is one the
most important elements of the Wnt-signaling pathway;
its activation is a general characteristic of solid tumors
such as bladder, prostate, and renal tumors. Epigenetic
down regulation of Wnt pathway inhibitors may contri-
bute to aberrant activation of Wnt signaling pathway
[24]. Hypermethylation of APC promoter can silence
gene expression by interfering with the binding of tran-
scription factors to the promoter [25]. According, with
our results, Uesugi and his colleagues have reported that
inactivation of the APC gene via hypermethylation has a
significant role in oral carcinogenesis [26].
Jing et al., (2010) have also reported an association
between hypermethylation of APC gene promoter and
breast cancer [27]. Furthermore, there are reports that
APC promoter hypermethylation is linked with H.
pylori-associated gastritis [28], cervical cancer [29], and
esophageal adenocarcinoma [30]. While our observa-
tions support the connection between APC hyper-
methylation with OSCC progression, this study did not
find any significant change in APC expression levels
between patients and controls. One explanation for
these observation may be due to the involvement of
other factors which reducee gene expression. Also,
since the number of tumor and control samples ana-
lyzed was relatively small it was not enough to estab-
lish a strong and significant relationship between
hypermethylation and gene expression for these genes.
Further analysis involving larger sample sizes are
needed to elucidate this matter.
Table 2 Relationship between ATM promptor methylation and clinicopathology parameters in healthy controls and
cases
Characteristics Controls
N=5 7
ATM methylation status P value Cases
N=8 4
ATM methylation status *P
value
Present
N (%)
Absent
N (%)
Present
N (%)
Absent
N (%)
Mean age 39.07 ± 14 54.14 ± 18
< 50 46 36(78.26) 10(21.74) 0.3 26 23(88.46) 3(11.54) 0.103
> 50 11 8(72.72) 3(27.28) 58 51(87.93) 7(12.07)
Sex
Male 21 17(80.95) 4(19.05) 0.6 40 34(85) 6(15) 0.404
Female 36 27(75) 9(25) 44 40(90.90) 4(9.1)
Stage
I 18 16(88.88) 2(11.12) 0.465
II - - - - 18 15(83.32) 3(16.68)
III 43 38(83.36) 5(11.64)
IV 5 5(100) 0
*Chi-square test
Table 3 Comparison of promoter methylation of APC and
ATAM genes in patients with oral cavity cancer and
healthy controls
Gene Methylation statuse Controls
N (%)
Cases
N (%)
*P value
APC Present 50 (87.71) 60 (71.42) 0.01
Absent 7 (12.29) 24 (28.58)
ATM Present 44 (77.19) 74 (88.09) 0.8
Absent 13 (22.81) 10 (11.91)
*Chi-square test
Table 4 Comparison of gene expression levels (2
-ΔΔCT)o f
ATM and APC between patients with oral cavity cancer
and healthy controls.
Gene N Mean ± SD P-value (Mann-Whitney test)
APC Cases 11 2.06 ± 2.6 0.3
Controls 10 0.95 ± 1.31
ATM Cases 9 0.5 ± 0.9 0.9
Controls 10 1.48 ± 2.2
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which is vital in signaling pathways of DNA damage.
ATM kinase activates and phosphorylates a number of
downstream regulatory proteins that are significant in
apoptosis, DNA repair, and cell cycle arrest [31]. Var-
ious reports have shown the association of ATM muta-
tion with risk of different human malignancies including
breast, prostate, and ovarian cancers, mantle cell lym-
phoma, and B-cell chronic lymphocytic leukemia. The
primary molecular pathway(s) by which ATM gene
leads to these alterations are not well known [32]. So
far, no study has shown strict involvement of ATM
gene methylation with OSCC.
The results of Wai et al., (2004) indicated 45% hyper-
methylation of ATM gene in fecal DNA of patients with
colorectal cancer and its lack in healthy controls [33]. This
has the potential to be used as predictive factor for patients
with non-small cell cancer [34] and thyroid carcinoma [35].
Vo QN et al., (2004) showed a link between decreased
ATM function due to epigenetic silencing and sporadic
breast malignancy [36]. On the contrary, a study on a
full range of B-cell lines with variable degrees of differ-
entiation showed that methylation of ATM gene is far
less frequent in lymphomagenesis compared to deletions
and mutations [37].
DNA methylation and histone modification emerge to
work together to silence the expression of a number of
genes in cancer, such as APC and hMLH1 [25,38]. How-
ever, our study has some limitations, it has been focus
on analysis of 2 genes so, identification of further novel
CpG islands that are specifically linked with OSCC will
be needed to create a panel with higher sensitivity that
maintains high specificity, and studies examining detec-
tion of such a panel of genes by newly developed quan-
titative assays should be undertaken.
Obviously, additional studies are needed to further
elucidate the relationship between DNA methylation,
demethylation, and histone modification in genes
regulation. Results from such research may support new
strategies and suggest further study with larger sample
size for better understanding of molecular mechanisms
of cancer, which play a critical role in prevention and
management of disease.
Materials and methods
Samples and DNA preparation
Eighty-four OSCC tissues that had been fixed in paraffin
along with 57 control oral mucosa were collected from
patients without history of OSCC who were referred to
Periodontics Department, Dental School, Zahedan Uni-
versity of Medical Sciences. All procedures in this study
were approved by the Ethical Board at the Zahedan Uni-
versity of Medical Sciences. Genomic DNA was
extracted using QIAamp DNA Kits from cancerous
(Cat. No. 56404, Qiagen) and healthy control (Cat.
No.51304, Qiagen) samples, and then its quality was
estimated by a spectrophotometer.
Methylation-Specific Polymerase Chain Reaction (MS-PCR)
The process of bisulfite conversion of DNA sampleswas
conducted as previously described [39]. MSP analysis of
promoter regions of APC and ATM was carried out in
25 μl PCR reactions containing 1 μlo fb i s u l f i t e - t r e a t e d
genomic DNA, oligonucleotide primers (25 pmol each/
reaction), dNTPs (200 μM each), 0.625 units of Hotstar
Taq (Qiagen, Valencia, CA) in 1× PCR buffer and 2.5
mM MgCl2. Thermo cycling conditions were carried
out using the following settings: 95°C for 10 min; 40
cycles consisting of [30 s at 95°C, 30 s at 61°C for APC
(M), 56°C (U) and for ATM 65°C (M), 60°C (U),1 min
at 72°C], and a final extension at 72°C for 10 min. Paral-
lel with each set of MSP reactions, positive and negative
controls were run. Ten microliters of each MSP reac-
tions were electrophoresed on 3.5% agarose gels and
were visualized by ethidium bromide staining. The list
of primers were utilized are giving in Table 5.
Table 5 Primer sequences and annealing temperature
Genes Sequences Annealing
temperature
APC M F:GAACCAAAACGCTCCCCAT
R:TTATATGTCGGTTACGTGCGTTTATAT
61
APC U F:AAACCAAAACACTCCCCATTC
R:AGTTATATGTTGGTTATGTGTGTTTAT
56
ATM M F:GGAGTTCGAGTCGAAGGG
R:CTACCTACTCCCGCTTCCGA
65
ATM U F:GTTTTGGAGTTTGAGTTGAAGGGT
R:AACTACCTACTCCCACTTCCAA
60
GAPDH (Real Time-PCR) F: CCACTCCTCCACCTTTGAC
R: ACCCTGTTGCTGTAGCCA
60
APC(Real Time-PCR) F:CTTCAAAATTACCTCCAC R:CTCCTCTAACTCCTTCTC 60
ATM(Real Time-PCR) F:CAGGGTAGTTTAGTTGAG GTTGACAG R:CTATACTGGTGGTCAGTGCCAAAGT 60
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We extracted total RNA from OSCC and control tissues
using the High pure RNA Tissue kit (Cat No:
12033674001) and High pure FFPE RNA Micro kit (Cat
No: 04823125001), respectively, according to the manu-
facturer’s instructions. The cDNA synthesis kit (Cat No:
K1611, Frmantase) was used for converting 1 μg of total
RNA to cDNA according to the manufacturer’s instruc-
tions. Real time-PCR of APC, ATM, and glyceralde-
hyde-3-phosphate dehydrogenize (GAPDH) were
performed using SYBR green assay by 7300 Real-Time
PCR System (Applied Biosystems, Foster City, CA).
Statistical analysis
Analysis of data was carried out using SPSS software
version 17.0 to evaluate association between methylation
status of APC and ATM genes and clinical parameters
by c2 and t tests. Assaying relative gene expression (2
-
ΔΔCT) between cases and controls were done by Mann-
Whitney test. Significance level was set at P < 0.05 for
all tests.
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